Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Diagnostics › Tissue-Based Testing › Novartis Seeks FDA OK for Drug With Favorable Phase III Results in PIK3CA-Mutated Breast Cancer

Novartis Seeks FDA OK for Drug With Favorable Phase III Results in PIK3CA-Mutated Breast Cancer

May 16, 2019
|
staff reporter

NEW YORK (GenomeWeb) – Novartis has filed a new drug application with the US Food and Drug Administration for its investigational drug alpelisib — an alpha-specific PI3 kinase inhibitor that shows promise for treating hormone receptor-positive, HER2-negative advanced breast cancers with PIK3CA mutations.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Aug
24
Featured Webinar

Utility of Novel RNA-Based Tools in Oncology Drug Development

Sponsored by
Genecentric

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Aug
25
Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

Sep
10
Featured Webinar

Development of RNA-Based Predictive Response Signatures as Companion Diagnostics

Sponsored by
Genecentric

This webinar, Part 2 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will focus on the development of RNA-based companion diagnostics for oncology.

Oct
08
Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

What's Popular?

In Cancer

  1. Guardant Health CDx Wins FDA Approval for First Liquid Biopsy NGS Tumor Profiling Assay

  2. Real-World, Umbrella Studies Highlight Challenges of Evaluating Precision Oncology in NSCLC

    Premium

  3. Singapore's Avatamed Raises $1M in Seed Funding

  4. UCSF Glioblastoma Projects Using Molecular Data to Inform Subtypes, Match Patients to Treatments

    Premium

  5. Genetic Testing Challenges in Oncology: Assuming All Labs Are Equal Gives False Reassurance of Risk

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.